Review of EMERALD Subgroup Analysis Data From SABCS 2023
January 22nd 2024Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.
Watch
Unmet Needs in the Treatment of Patients With Metastatic Breast Cancer With Visceral Metastases
January 22nd 2024Virginia Kaklamani, MD, DSc, reviews the presented case of a postmenopausal patient with breast cancer who develops metastases after adjuvant endocrine therapy ends, and explains that later treatment selection is difficult because of endocrine resistance and mutations causing more aggressive disease.
Watch